Brief: HLS Therapeutics Announces Q1 Fiscal 2022 Financial Results
05/05/2022 12:59
May 5 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS ANNOUNCES Q1 FISCAL 2022 FINANCIAL
RESULTS
* Q1 LOSS PER SHARE $0.11
* Q1 REVENUE $14.6 MILLION VERSUS $14.3 MILLION
* Q1 EARNINGS PER SHARE VIEW $-0.10, REVENUE VIEW $15.6
MILLION --
REFINITIV IBES DATA
Source text for Eikon: ID:nCNWt5S8Qa
Further company coverage: HLS.TO
((reuters.briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease